High Pretreatment Platelet-to-Albumin Ratio Predicts Poor Survival Results in Locally Advanced Nasopharyngeal Cancers Treated with Chemoradiotherapy

Veysel Haksoyler,1 Erkan Topkan2 1Medline Hospital, Department of Medical Oncology, Adana, Turkey; 2Baskent University Medical Faculty, Department of Radiation Oncology, Adana, TurkeyCorrespondence: Erkan TopkanBaskent University Medical Faculty, Department of Radiation Oncology, Adana, 01120, Turke...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Haksoyler V, Topkan E
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	concurrent chemoradiotherapy nasopharyngeal cancer platelet-to-albumin ratio prognostic worth survival results Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/46d3d20cdbce41f988498a7c86f0868a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:46d3d20cdbce41f988498a7c86f0868a
record_format	dspace
spelling	oai:doaj.org-article:46d3d20cdbce41f988498a7c86f0868a2021-12-02T16:29:39ZHigh Pretreatment Platelet-to-Albumin Ratio Predicts Poor Survival Results in Locally Advanced Nasopharyngeal Cancers Treated with Chemoradiotherapy1178-203Xhttps://doaj.org/article/46d3d20cdbce41f988498a7c86f0868a2021-07-01T00:00:00Zhttps://www.dovepress.com/high-pretreatment-platelet-to-albumin-ratio-predicts-poor-survival-res-peer-reviewed-fulltext-article-TCRMhttps://doaj.org/toc/1178-203XVeysel Haksoyler,1 Erkan Topkan2 1Medline Hospital, Department of Medical Oncology, Adana, Turkey; 2Baskent University Medical Faculty, Department of Radiation Oncology, Adana, TurkeyCorrespondence: Erkan TopkanBaskent University Medical Faculty, Department of Radiation Oncology, Adana, 01120, TurkeyTel +90-533-7381069Fax +90-322-3444452Email docdretopkan@gmail.comPurpose: In a lack of similar research, we assessed the prognostic utility of pretreatment platelet-to-albumin ratio (PAR) in locally advanced nasopharyngeal carcinoma (LANPC) patients managed with concurrent chemoradiotherapy (CCRT).Patients and Methods: Present retrospective analysis included a sum of 128 consecutively treated LANPC patients who underwent cisplatinum-based radical CCRT. Availability of an ideal pretreatment PAR cutoff that may stratify the study population into two cohorts with significantly distinct survival outcomes was sought by utilizing the receiver operating characteristic (ROC) curve analysis. The primary and secondary endpoints were overall survival (OS) and progression-free survival (PFS), respectively.Results: A rounded 5.2 [area under the curve (AUC): 68.9%; sensitivity: 67.4%; and specificity: 65.2%] value was identified as the ideal PAR cutoff that grouped patients into two gatherings [PAR≥ 5.2 (N=60) versus < 5.2 (N=68)]. The median follow-up duration was 86.4 months (range: 9– 147). Kaplan–Meier comparisons between the two PAR groups revealed significantly diminished median PFS (69.4 versus 106.8 months for PAR< 5.2; P< 0.012) and OS (88.3 versus not reached yet for PAR< 5.2; P= 0.023) for the PAR ≥ 5.2 group. The results of multivariate analyses affirmed the pretreatment PAR≥ 5.2 as an independent prognostic factor that indicates diminished PFS (P= 0.016) and OS (P= 0.019) together with the respective N2-3 nodal stage (versus N0-1; P< 0.05 for PFS and OS, respectively) and weight loss > 5% at past six months (≤ 5%; P< 0.05 for PFS and OS, respectively).Conclusion: The results of the current retrospective analysis provided a robust and independent adverse prognostic value for pretreatment PAR ≥ 5.2 in terms of median and long-term PFS and OS outcomes in LA-NPC patients this patient group treated with conclusive CCRT.Keywords: concurrent chemoradiotherapy nasopharyngeal cancer, platelet-to-albumin ratio, prognostic worth, survival resultsHaksoyler VTopkan EDove Medical Pressarticleconcurrent chemoradiotherapy nasopharyngeal cancerplatelet-to-albumin ratioprognostic worthsurvival resultsTherapeutics. PharmacologyRM1-950ENTherapeutics and Clinical Risk Management, Vol Volume 17, Pp 691-700 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	concurrent chemoradiotherapy nasopharyngeal cancer platelet-to-albumin ratio prognostic worth survival results Therapeutics. Pharmacology RM1-950
spellingShingle	concurrent chemoradiotherapy nasopharyngeal cancer platelet-to-albumin ratio prognostic worth survival results Therapeutics. Pharmacology RM1-950 Haksoyler V Topkan E High Pretreatment Platelet-to-Albumin Ratio Predicts Poor Survival Results in Locally Advanced Nasopharyngeal Cancers Treated with Chemoradiotherapy
description	Veysel Haksoyler,1 Erkan Topkan2 1Medline Hospital, Department of Medical Oncology, Adana, Turkey; 2Baskent University Medical Faculty, Department of Radiation Oncology, Adana, TurkeyCorrespondence: Erkan TopkanBaskent University Medical Faculty, Department of Radiation Oncology, Adana, 01120, TurkeyTel +90-533-7381069Fax +90-322-3444452Email docdretopkan@gmail.comPurpose: In a lack of similar research, we assessed the prognostic utility of pretreatment platelet-to-albumin ratio (PAR) in locally advanced nasopharyngeal carcinoma (LANPC) patients managed with concurrent chemoradiotherapy (CCRT).Patients and Methods: Present retrospective analysis included a sum of 128 consecutively treated LANPC patients who underwent cisplatinum-based radical CCRT. Availability of an ideal pretreatment PAR cutoff that may stratify the study population into two cohorts with significantly distinct survival outcomes was sought by utilizing the receiver operating characteristic (ROC) curve analysis. The primary and secondary endpoints were overall survival (OS) and progression-free survival (PFS), respectively.Results: A rounded 5.2 [area under the curve (AUC): 68.9%; sensitivity: 67.4%; and specificity: 65.2%] value was identified as the ideal PAR cutoff that grouped patients into two gatherings [PAR≥ 5.2 (N=60) versus < 5.2 (N=68)]. The median follow-up duration was 86.4 months (range: 9– 147). Kaplan–Meier comparisons between the two PAR groups revealed significantly diminished median PFS (69.4 versus 106.8 months for PAR< 5.2; P< 0.012) and OS (88.3 versus not reached yet for PAR< 5.2; P= 0.023) for the PAR ≥ 5.2 group. The results of multivariate analyses affirmed the pretreatment PAR≥ 5.2 as an independent prognostic factor that indicates diminished PFS (P= 0.016) and OS (P= 0.019) together with the respective N2-3 nodal stage (versus N0-1; P< 0.05 for PFS and OS, respectively) and weight loss > 5% at past six months (≤ 5%; P< 0.05 for PFS and OS, respectively).Conclusion: The results of the current retrospective analysis provided a robust and independent adverse prognostic value for pretreatment PAR ≥ 5.2 in terms of median and long-term PFS and OS outcomes in LA-NPC patients this patient group treated with conclusive CCRT.Keywords: concurrent chemoradiotherapy nasopharyngeal cancer, platelet-to-albumin ratio, prognostic worth, survival results
format	article
author	Haksoyler V Topkan E
author_facet	Haksoyler V Topkan E
author_sort	Haksoyler V
title	High Pretreatment Platelet-to-Albumin Ratio Predicts Poor Survival Results in Locally Advanced Nasopharyngeal Cancers Treated with Chemoradiotherapy
title_short	High Pretreatment Platelet-to-Albumin Ratio Predicts Poor Survival Results in Locally Advanced Nasopharyngeal Cancers Treated with Chemoradiotherapy
title_full	High Pretreatment Platelet-to-Albumin Ratio Predicts Poor Survival Results in Locally Advanced Nasopharyngeal Cancers Treated with Chemoradiotherapy
title_fullStr	High Pretreatment Platelet-to-Albumin Ratio Predicts Poor Survival Results in Locally Advanced Nasopharyngeal Cancers Treated with Chemoradiotherapy
title_full_unstemmed	High Pretreatment Platelet-to-Albumin Ratio Predicts Poor Survival Results in Locally Advanced Nasopharyngeal Cancers Treated with Chemoradiotherapy
title_sort	high pretreatment platelet-to-albumin ratio predicts poor survival results in locally advanced nasopharyngeal cancers treated with chemoradiotherapy
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/46d3d20cdbce41f988498a7c86f0868a
work_keys_str_mv	AT haksoylerv highpretreatmentplatelettoalbuminratiopredictspoorsurvivalresultsinlocallyadvancednasopharyngealcancerstreatedwithchemoradiotherapy AT topkane highpretreatmentplatelettoalbuminratiopredictspoorsurvivalresultsinlocallyadvancednasopharyngealcancerstreatedwithchemoradiotherapy
_version_	1718383926989291520

High Pretreatment Platelet-to-Albumin Ratio Predicts Poor Survival Results in Locally Advanced Nasopharyngeal Cancers Treated with Chemoradiotherapy

Ejemplares similares